Covalent inhibitors of KRASG12C (KRASi) hold considerable progress for tumors driven by this oncogene yet early studies suggest rapid mechanisms of adaptive resistance that appear cell type dependent.

NIAID Data Ecosystem50

Inhibiting KRAS G12C with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS G12C and immune checkpoint inhibitor therapy. Hirade et al.

KRAS靶向治疗

Westernblot实验验证

Uncropped image of the Western blots

Mendeley Data00

Supplementary Table S4 from Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy

合成致死筛选

KRAS靶向治疗

Supplementary Table S4 MaGeCK analysis of MRTX-849/TNO155 CRISPR/Cas9 screens of NSCLC cell lines

Figshare2023-12-15 更新60

Anti-tumor Efficacy of HRS-4642 and Its Potential Combination with Proteasome Inhibition in KRAS G12D-mutant Cancer

KRAS靶向治疗

组合疗法

KRAS G12D is the most frequently mutated oncogenic KRAS subtype in solid tumors and remains undruggable in clinical settings. Here, we developed a high affinity, selective, long-acting, and non-covale

NIAID Data Ecosystem00

MRTX1257 KRAS G12Ci in 3 KRAS-G12C mutant cancer cell lines

资源简介：

相关数据集